Tricuspid Regurgitation Medication

Author: Mary C Mancini, MD, PhD; Chief Editor: Richard A Lange, MD more...

Updated: Sep 27, 2011

What would you like to print?

Medication Summary
Diuretics
Cardiac glycosides
Angiotensin-converting enzyme (ACE) inhibitors
Anticoagulants
Show All

Medication Summary

The medical therapy used in the treatment of tricuspid regurgitation is directed toward the control of CHF that is causing or contributing to the problem.

Class Summary

Are used to control the fluid overload associated with the process.

View full drug information

Furosemide (Lasix)

Increases excretion of water by interfering with chloride-binding cotransport system, which in turn inhibits sodium and chloride reabsorption in ascending loop of Henle and distal renal tubule. Dose must be individualized to the patient. Depending on response, administer at increments of 20-40 mg, no sooner than 6-8 h after the previous dose, until desired diuresis occurs. When treating infants, titrate with 1 mg/kg/dose increments until a satisfactory effect is achieved.

Class Summary

These drugs (primarily digoxin) are used to control atrial fibrillation and to increase myocardial contractility.

View full drug information

Digoxin (Lanoxin)

Cardiac glycoside with direct inotropic effects in addition to indirect effects on the cardiovascular system. Acts directly on cardiac muscle, increasing myocardial systolic contractions. Its indirect actions result in increased carotid sinus nerve activity and enhanced sympathetic withdrawal for any given increase in mean arterial pressure.

Class Summary

Are used to provide afterload reduction, thereby decreasing the volume load on the right ventricle.

View full drug information

Captopril (Capoten)

Prevents conversion of angiotensin I to angiotensin II, a potent vasoconstrictor, resulting in increased levels of plasma renin and a reduction in aldosterone secretion.

Class Summary

Are used to prevent thrombosis and embolization from the prosthetic valve used in the treatment of tricuspid regurgitation.

View full drug information

Warfarin (Coumadin)

Interferes with hepatic synthesis of vitamin K–dependent coagulation factors. Used for prophylaxis and treatment of venous thrombosis, pulmonary embolism, and thromboembolic disorders. Tailor dose to maintain an international normalized ratio (INR) in the range of 2-3.

Proceed to Follow-up

Contributor Information and Disclosures

Author

Mary C Mancini, MD, PhD Professor and Chief of Cardiothoracic Surgery, Department of Surgery, Louisiana State University School of Medicine in Shreveport

Mary C Mancini, MD, PhD is a member of the following medical societies: American Association for Thoracic Surgery, American College of Surgeons, American Surgical Association, Phi Beta Kappa, Society of Thoracic Surgeons, and Southern Surgical Association

Disclosure: Nothing to disclose.

Specialty Editor Board

Martin Keane, MD, FACC, FAHA Associate Professor, Cardiovascular Medicine Division, Department of Medicine, University of Pennsylvania School of Medicine

Martin Keane, MD, FACC, FAHA is a member of the following medical societies: Alpha Omega Alpha, American College of Cardiology, American College of Physicians, American College of Physicians-American Society of Internal Medicine, American Heart Association, American Society of Echocardiography, Pennsylvania Medical Society, and Phi Beta Kappa

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Ronald J Oudiz, MD, FACP, FACC, FCCP Professor of Medicine, University of California, Los Angeles, David Geffen School of Medicine; Director, Liu Center for Pulmonary Hypertension, Division of Cardiology, LA Biomedical Research Institute at Harbor-UCLA Medical Center

Ronald J Oudiz, MD, FACP, FACC, FCCP is a member of the following medical societies: American College of Cardiology, American College of Chest Physicians, American College of Physicians, American Heart Association, and American Thoracic Society

Disclosure: Actelion Grant/research funds Clinical Trials + honoraria; Encysive Grant/research funds Clinical Trials + honoraria; Gilead Grant/research funds Clinical Trials + honoraria; Pfizer Grant/research funds Clinical Trials + honoraria; United Therapeutics Grant/research funds Clinical Trials + honoraria; Lilly Grant/research funds Clinical Trials + honoraria; LungRx Clinical Trials + honoraria; Bayer Grant/research funds Consulting

Amer Suleman, MD Private Practice

Amer Suleman, MD is a member of the following medical societies: American College of Physicians, American Heart Association, American Institute of Stress, American Society of Hypertension, Federation of American Societies for Experimental Biology, Royal Society of Medicine, and Society of Cardiac Angiography and Interventions

Disclosure: Nothing to disclose.

Chief Editor

Richard A Lange, MD Professor and Executive Vice Chairman, Department of Medicine, Director, Office of Educational Programs, University of Texas Health Science Center at San Antonio

Richard A Lange, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Cardiology, American Heart Association, and Association of Subspecialty Professors

Disclosure: Nothing to disclose.

Additional Contributors

The authors and editors of eMedicine gratefully acknowledge the contributions of previous author Frank Sheridan, MD to the development and writing of this article.

References

Frater R. Tricuspid insufficiency. J Thorac Cardiovasc Surg. Sep 2001;122(3):427-9. [Medline].
Topilsky Y, Tribouilloy C, Michelena HI, Pislaru S, Mahoney DW, Enriquez-Sarano M. Pathophysiology of tricuspid regurgitation: quantitative Doppler echocardiographic assessment of respiratory dependence. Circulation. Oct 12 2010;122(15):1505-13. [Medline].
Sugimoto T, Okada M, Ozaki N, et al. Long-term evaluation of treatment for functional tricuspid regurgitation with regurgitant volume: characteristic differences based on primary cardiac lesion. J Thorac Cardiovasc Surg. Mar 1999;117(3):463-71. [Medline].
Khan IA. Ebstein's anomaly of the tricuspid valve with associated mitral valve prolapse. Tex Heart Inst J. 2001;28(1):72. [Medline].
Simula DV, Edwards WD, Tazelaar HD, et al. Surgical pathology of carcinoid heart disease: a study of 139 valves from 75 patients spanning 20 years. Mayo Clin Proc. Feb 2002;77(2):139-47. [Medline].
Luo GH, Ma WG, Sun HS, et al. Correction of traumatic tricuspid insufficiency using the double orifice technique. Asian Cardiovasc Thorac Ann. Sep 2005;13(3):238-40. [Medline].
Ha JW, Chung N, Jang Y, Rim SJ. Tricuspid stenosis and regurgitation: Doppler and color flow echocardiography and cardiac catheterization findings. Clin Cardiol. Jan 2000;23(1):51-2. [Medline].
Shah PM, Raney AA. Tricuspid valve disease. Curr Probl Cardiol. Feb 2008;33(2):47-84. [Medline].
Vlahos AP, Feinstein JA, Schiller NB, Silverman NH. Extension of Doppler-derived Echocardiographic Measures of Pulmonary Vascular Resistance to Patients with Moderate or Severe Pulmonary Vascular Disease. J Am Soc Echocardiogr. Jan 8 2008;[Medline].
Yang WI, Shim CY, Kang MK, et al. Vena contracta width as a predictor of adverse outcomes in patients with severe isolated tricuspid regurgitation. J Am Soc Echocardiogr. Sep 2011;24(9):1013-9. [Medline].
Topilsky Y, Khanna AD, Oh JK, et al. Preoperative factors associated with adverse outcome after tricuspid valve replacement. Circulation. May 10 2011;123(18):1929-39. [Medline].
Anderson C, Filsoufi F, Farivar RS, Adams DH. Optimal management of severe tricuspid regurgitation in cardiac transplant recipients. J Heart Lung Transplant. Feb 2001;20(2):247. [Medline].
DeLeon MA, Gidding SS, Gotteiner N, Backer CL, Mavroudis C. Successful palliation of Ebstein's malformation on the first day of life following fetal diagnosis. Cardiol Young. Oct 2000;10(4):384-7. [Medline].
Filsoufi F, Anyanwu AC, Salzberg SP, et al. Long-term outcomes of tricuspid valve replacement in the current era. Ann Thorac Surg. Sep 2005;80(3):845-50. [Medline].
Gatti G, Maffei G, Lusa AM, Pugliese P. Tricuspid valve repair with the Cosgrove-Edwards annuloplasty system: early clinical and echocardiographic results. Ann Thorac Surg. Sep 2001;72(3):764-7. [Medline].
Roberts PA, Boudjemline Y, Cheatham JP. Percutaneous Tricuspid Valve Replacement in Congenital and Acquired Heart Disease. JACC. 2011;58:117-22.
Abrams DJ, Kilner P, Till JA, et al. Prolapse of the antero-superior leaflet of the tricuspid valve secondary to congenital anomalies of the valvar and sub-valvar apparatus: a rare cause of severe tricuspid regurgitation. Cardiol Young. Aug 2005;15(4):417-21. [Medline].
Burgess MI, Aziz T, Yonan N. Clinical relevance of subclinical tricuspid regurgitation after orthotopic cardiac transplantation. J Am Soc Echocardiogr. Feb 1999;12(2):164. [Medline].
Daniels SJ, Mintz GS, Kotler MN. Rheumatic tricuspid valve disease: two-dimensional echocardiographic, hemodynamic, and angiographic correlations. Am J Cardiol. Feb 1983;51(3):492-6. [Medline].
Hachiro Y, Sugimoto S, Takagi N, et al. Native valve salvage for post-traumatic tricuspid regurgitation. J Heart Valve Dis. Mar 2001;10(2):276-8. [Medline].
Kanzaki H, Nakatani S, Kawada T, et al. Right ventricular dP/dt/P(max), not dP/dt(max), noninvasively derived from tricuspid regurgitation velocity is a useful index of right ventricular contractility. J Am Soc Echocardiogr. Feb 2002;15(2):136-42. [Medline].
Krupa W, Kozlowski D, Derejko P, Swiatecka G. Permanent cardiac pacing and its influence on tricuspid valve function. Folia Morphol (Warsz). Nov 2001;60(4):249-57. [Medline].
Kuwaki K, Morishita K, Tsukamoto M, Abe T. Tricuspid valve surgery for functional tricuspid valve regurgitation associated with left-sided valvular disease. Eur J Cardiothorac Surg. Sep 2001;20(3):577-82. [Medline].
Leszek P, Zielinski T, Rozanski J, et al. Traumatic tricuspid valve insufficiency: case report. J Heart Valve Dis. Jul 2001;10(4):545-7. [Medline].
Mansencal N, Mourvillier B, Schwob J, et al. Asymptomatic traumatic tricuspid regurgitation: a case report with an early diagnosis. Ann Emerg Med. Feb 2002;39(2):205. [Medline].
Matsunaga A, Duran CM. Progression of tricuspid regurgitation after repaired functional ischemic mitral regurgitation. Circulation. Aug 30 2005;112(9 Suppl):I453-7. [Medline].
Messing B, Porat S, Imbar T, et al. Mild tricuspid regurgitation: a benign fetal finding at various stages of pregnancy. Ultrasound Obstet Gynecol. Nov 2005;26(6):606-9; discussion 610. [Medline].
Motoyoshi N, Tofukuji M, Sakurai M, et al. Cleft on tricuspid anterior leaflet. Ann Thorac Surg. Apr 2001;71(4):1350-1. [Medline].
Numata S, Uemura H, Yagihara T, et al. Replacement of the morphologically tricuspid valve in children with discordant atrioventricular connections. J Heart Valve Dis. Nov 1999;8(6):649-54. [Medline].
Oliver JM, Gallego P, Gonzalez A, et al. Predisposing conditions for atrial fibrillation in atrial septal defect with and without operative closure. Am J Cardiol. Jan 1 2002;89(1):39-43. [Medline].
Smrcek JM, Krapp M, Axt-Fliedner R, et al. Atypical ductus venosus blood flow pattern in fetuses with severe tricuspid valve regurgitation. Ultrasound Obstet Gynecol. Aug 2005;26(2):180-2. [Medline].
Tribouilloy CM, Enriquez-Sarano M, Bailey KR, et al. Quantification of tricuspid regurgitation by measuring the width of the vena contracta with Doppler color flow imaging: a clinical study. J Am Coll Cardiol. Aug 2000;36(2):472-8. [Medline].
Trojnarska O, Szyszka A, Gwizdala A, et al. Adults with Ebstein's anomaly-Cardiopulmonary exercise testing and BNP levels Exercise capacity and BNP in adults with Ebstein's anomaly. Int J Cardiol. Oct 18 2005;[Medline].
Yiwu L, Yingchun C, Jianqun Z, et al. Exact quantitative selective annuloplasty of the tricuspid valve. J Thorac Cardiovasc Surg. Sep 2001;122(3):611-4. [Medline].